CN101475642A - 一种艾滋病毒重组抗原及其融合蛋白 - Google Patents
一种艾滋病毒重组抗原及其融合蛋白 Download PDFInfo
- Publication number
- CN101475642A CN101475642A CN200810217510.9A CN200810217510A CN101475642A CN 101475642 A CN101475642 A CN 101475642A CN 200810217510 A CN200810217510 A CN 200810217510A CN 101475642 A CN101475642 A CN 101475642A
- Authority
- CN
- China
- Prior art keywords
- hiv
- antigen
- protein
- hivag
- recombinant protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title abstract description 128
- 108091007433 antigens Proteins 0.000 title abstract description 120
- 102000036639 antigens Human genes 0.000 title abstract description 119
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 title description 69
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 49
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 14
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims abstract description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 38
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 31
- 235000018102 proteins Nutrition 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 239000013600 plasmid vector Substances 0.000 claims description 9
- 238000009736 wetting Methods 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 230000008034 disappearance Effects 0.000 claims description 6
- 238000003149 assay kit Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical group 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 30
- 230000035945 sensitivity Effects 0.000 abstract description 16
- 238000001514 detection method Methods 0.000 abstract description 15
- 239000006228 supernatant Substances 0.000 abstract description 14
- 241000588724 Escherichia coli Species 0.000 abstract description 10
- 230000036039 immunity Effects 0.000 abstract description 4
- 238000012408 PCR amplification Methods 0.000 abstract description 3
- 230000004927 fusion Effects 0.000 description 56
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 32
- 208000030507 AIDS Diseases 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 17
- 230000002285 radioactive effect Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 239000010931 gold Substances 0.000 description 12
- 229910052737 gold Inorganic materials 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 238000005267 amalgamation Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000000084 colloidal system Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000003000 inclusion body Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000032696 parturition Effects 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000002460 imidazoles Chemical class 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 108700004025 env Genes Proteins 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 238000002525 ultrasonication Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- -1 electroselenium Chemical compound 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- VOZKAJLKRJDJLL-UHFFFAOYSA-N 2,4-diaminotoluene Chemical compound CC1=CC=C(N)C=C1N VOZKAJLKRJDJLL-UHFFFAOYSA-N 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910021505 gold(III) hydroxide Inorganic materials 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Substances OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical class O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical class OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810217510.9A CN101475642B (zh) | 2008-11-07 | 2008-11-07 | 一种艾滋病毒重组抗原及其融合蛋白 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810217510.9A CN101475642B (zh) | 2008-11-07 | 2008-11-07 | 一种艾滋病毒重组抗原及其融合蛋白 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101475642A true CN101475642A (zh) | 2009-07-08 |
CN101475642B CN101475642B (zh) | 2013-06-05 |
Family
ID=40836425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810217510.9A Active CN101475642B (zh) | 2008-11-07 | 2008-11-07 | 一种艾滋病毒重组抗原及其融合蛋白 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101475642B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106632691A (zh) * | 2016-12-29 | 2017-05-10 | 菲鹏生物股份有限公司 | Hiv重组抗原、表达基因、表达载体以及hiv检测试剂盒 |
CN110066343A (zh) * | 2019-05-23 | 2019-07-30 | 北京新创生物工程有限公司 | 一种用于检测hiv新发感染的重组抗原及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0572737B1 (en) * | 1992-06-04 | 2001-02-28 | The Research Foundation For Microbial Diseases Of Osaka University | HIV Gag-env fusion antigen |
CN100575491C (zh) * | 2003-09-18 | 2009-12-30 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 跨膜型和分泌型HIV Gag抗原编码基因及包含其的艾滋病疫苗 |
-
2008
- 2008-11-07 CN CN200810217510.9A patent/CN101475642B/zh active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106632691A (zh) * | 2016-12-29 | 2017-05-10 | 菲鹏生物股份有限公司 | Hiv重组抗原、表达基因、表达载体以及hiv检测试剂盒 |
CN110066343A (zh) * | 2019-05-23 | 2019-07-30 | 北京新创生物工程有限公司 | 一种用于检测hiv新发感染的重组抗原及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101475642B (zh) | 2013-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111239394B (zh) | 一种基于混合抗原快速检测新型冠状病毒抗体试剂盒 | |
CN111285933A (zh) | 一种新型冠状病毒抗原胶体金诊断试剂盒 | |
CN103396481B (zh) | 一种二型登革热病毒ns1蛋白的重链单域抗体及其制备方法和应用 | |
CN107573417A (zh) | 肺炎支原体嵌合抗原、该抗原检测试剂及两者的制备方法 | |
CN113740536B (zh) | 一种非洲猪瘟病毒p30阻断ELISA抗体检测试剂盒及其应用 | |
CN112175086A (zh) | 一种抗猪流行性腹泻病毒nsp13蛋白的单克隆抗体及应用 | |
CN106885903B (zh) | 一种寨卡病毒e抗原及其在检测抗寨卡病毒抗体中的应用 | |
CN109613240A (zh) | 一种用于检测hiv的试剂盒 | |
CN102492041B (zh) | Hiv重组融合抗原及其表达基因和制备方法 | |
CN101403746B (zh) | 用于免疫检测的缀合物 | |
CN114957454B (zh) | 一种抗csfv e2蛋白的纳米抗体、融合蛋白及其制备方法和应用 | |
CN101475642B (zh) | 一种艾滋病毒重组抗原及其融合蛋白 | |
CN101962411B (zh) | 登革病毒血清学早期诊断试剂 | |
CN106632618A (zh) | 一种猪戊型肝炎病毒orf2重组蛋白的制备方法及其orf2蛋白和检测试剂盒 | |
WO1993024630A1 (en) | Reagent for agglutination assays | |
CN109593130A (zh) | 乙型肝炎病毒前s1抗原特异性单链抗体及其应用 | |
CN113687073B (zh) | 一种非洲猪瘟病毒p54阻断ELISA抗体检测试剂盒及其应用 | |
CN110066343A (zh) | 一种用于检测hiv新发感染的重组抗原及其应用 | |
CN102621305B (zh) | 猪巨细胞病毒抗体间接阻断elisa检测试剂盒及其检测方法 | |
CN110951703B (zh) | 一种间日疟原虫乳酸脱氢酶重组蛋白及其单克隆抗体的制备 | |
AU627738B2 (en) | Htlv-i / hiv-1 fusion proteins | |
CN105037555B (zh) | 缀合物及其制备方法和应用 | |
CA1321765C (en) | Immunodiagnostic assays using chimeric antigens | |
CN106198974A (zh) | 一种快速检测虹鳟鱼血清中ihnv抗体的elisa检测试剂盒 | |
WO1991007510A1 (en) | A method of detecting htlv-i antibodies in human body fluids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Shenzhen Feipeng biological Co.,Ltd. Sun Xingbao Document name: Notification of an Office Action |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 518057 Guangdong city of Shenzhen province Nanshan District Xili liuxiandong Zhongshan Road No. 1001 TCL Science Park building D2 building 6 floor Applicant after: Shenzhen Feipeng Biological Co.,Ltd. Address before: 518054 Guangdong city of Shenzhen province Nanshan District Nanshan Road Nanyou fourth industrial district three building six floor East Applicant before: Shenzhen Feipeng Biological Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Hongyan Inventor after: Liu Lili Inventor after: He Zhiqiang Inventor before: Sun Jing Inventor before: Sun Xingbao Inventor before: He Zhiqiang Inventor before: Li Hongyan |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: SUN JING SUN XINGBAO HE ZHIQIANG LI HONGYAN TO: LI HONGYAN LIU LILI HE ZHIQIANG |
|
C56 | Change in the name or address of the patentee |
Owner name: FAPON BIOTECH CORP. Free format text: FORMER NAME: SHENZHEN FAPON BIOTECH INC. |
|
CP03 | Change of name, title or address |
Address after: 518000 Guangdong city of Shenzhen province Nanshan District Xili liuxiandong Zhongshan Road No. 1001 TCL Science Park building D2 building 6 floor Patentee after: FAPON BIOTECH Inc. Address before: 518057 Guangdong city of Shenzhen province Nanshan District Xili liuxiandong Zhongshan Road No. 1001 TCL Science Park building D2 building 6 floor Patentee before: Shenzhen Feipeng Biological Co.,Ltd. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: He Zhiqiang Inventor after: Fan Lingyun Inventor after: Liu Lili Inventor after: Yang Gengzhou Inventor after: Wang Yiqiong Inventor before: Li Hongyan Inventor before: Liu Lili Inventor before: He Zhiqiang |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: AIDS virus recombinant antigen and fusion protein thereof Effective date of registration: 20200313 Granted publication date: 20130605 Pledgee: Shenzhen hi tech investment small loan Co.,Ltd. Pledgor: FAPON BIOTECH Inc. Registration number: Y2020980000699 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210616 Granted publication date: 20130605 Pledgee: Shenzhen hi tech investment small loan Co.,Ltd. Pledgor: FAPON BIOTECH Inc. Registration number: Y2020980000699 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |